Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 475-477

  Brodsky, Sergey V ^a   Rovin, Brad H ^a   Hebert, Lee A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

acute kidney injury; anticoagulation; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; HEPARIN; MIZORIBINE; PLACEBO; PREDNISONE; WARFARIN;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADULT; CHILD; COHORT STUDIES; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; WARFARIN;

EID: 84856843238     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr559     Document Type: Article

References (20)

1. Kamei K, Nakanishi K, Ito S et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 1301-1307
2. Brodsky SV, Satoskar A, Chen J et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54: 1121-1126
3. Brodsky SV, Collins M, Park E et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115: c142-c146
4. Brodsky SV, Nadasdy T, Rovin BH et al. Evidence that warfarin related nephropathy occurs commonly in both those with and without chronic kidney disease and is associated with increased mortality rate. Kidney Int 2011; 80: 181-189
5. Ware K, Brodsky P, Satoskar AA et al. Excessive anticoagulation of 5/6 nephrectomy rats with brodifacoum creates a rodent model of warfarin-related nephropathy. J Am Soc Nephrol 2011; [Epub ahead of print]
6. Walker RG, Yu SH, Owen JE et al. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103-107
7. Woo KT, Chiang GS, Lim CH. Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clin Nephrol 1987; 28: 304-305
8. Woo KT, Lee GS, Pall AA. Dipyridamole and low-dose warfarin without cyclophosphamide in the management of IgA nephropathy. Kidney Int 2000; 57: 348-349
9. Nolin L, Courteau M. Management of IgA nephropathy: evidencebased recommendations. Kidney Int Suppl 1999; 70: S56-S62
10. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
11. Woo KT, Lee GS. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin. Clin Nephrol 1991; 35: 184
12. Kanno Y, Witt M, Okada H et al. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clin Exp Nephrol 2003; 7: 48-51
13. Ishii T, Kawamura T, Tsuboi N et al. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy. Contrib Nephrol 2007; 157: 114-119
14. Yoshikawa N, Nakanishi K, Ishikura K et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol 2008; 23: 757-763
15. Kawasaki Y, Hosoya M, Suzuki J et al. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy. Am J Nephrol 2004; 24: 576-581
16. Shima Y, Nakanishi K, Kamei K et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant 2011; 26: 163-169
17. Taji Y, Kuwahara T, Shikata S et al. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006; 10: 268-273
18. Guo G, Morrissey J, McCracken R et al. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 2001; 280: F777-F785
19. McKinley A, Park E, Spetie D et al. Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol 2009; 4: 1754-1760
20. Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol 2007; 18: 2806-2809